SCHEMBL6873309

SCHEMBL6873309

CO[C@@H]1O[C@@](CO)(OC)[C@H]2OC(C)(C)O[C@@H]12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21694344 0.79
SCHEMBL20444744 0.79
SCHEMBL5555811 0.79
SCHEMBL22798495 0.72
SCHEMBL22797631 0.72
SCHEMBL22707383 0.70
SCHEMBL22707370 0.70
SCHEMBL21122594 0.70
SCHEMBL24673045 0.70
SCHEMBL22797567 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831069-B2 Having substituents at the C4' and C5' positions of the ribofuranose moiety; anticancer and immunomodulating effects at reduced cytotoxicity; treating autoimmune diseases, cancer, dermatitis RIBAPHARM INC. 2004-12-14 US disclosed
EP-1212326-A4 PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS ICN PHARMACEUTICALS (US) 2003-08-20 EP disclosed
EP-1212326-A1 PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS ICN Pharmaceuticals, Inc. (US) 2002-06-12 EP disclosed
US-20020035077-A1 Pyrrolo[2,3-d]pyrimidine nucleoside analogs CEQUENT PHARMACEUTICALS, INC. 2002-03-21 US disclosed
WO-2001027114-A1 PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS ICN PHARMACEUTICALS, INC. (US) 2001-04-19 WO disclosed